Universal reference book for medicines
Product name: PANTOGAM ® (PANTOHAM)

Active substance: hopantenic acid

Type: Nootropic drug with anticonvulsant action

Manufacturer: PIK-PHARMA (Russia) manufactured by PIK-PHARMA PRO (Russia)
Composition, form of production and packaging
Tablets of
white color, flat-cylindrical, with a facet and a risk.

1 tab.

calcium salt of gopantenic acid 250 mg

Excipients: methyl cellulose - 0.8 mg, calcium stearate - 3.1 mg, magnesium hydroxycarbonate - 46.8 mg, talc - 9.3 mg.

10 pieces.
- packings cellular planimetric (5) - packs cardboard.
Tablets of white color, flat-cylindrical, with a facet and a risk.

1 tab.

calcium salt of gopantenic acid 500 mg

Excipients: methylcellulose - 1.6 mg, calcium stearate - 6.2 mg, magnesium hydroxycarbonate - 93.6 mg, talc - 18.6 mg.

10 pieces.
- Packings contour mesh (5) - packs cardboard.
A 100 mg / ml syrup is colorless or slightly yellowish, with a cherry smell.

5 ml of 1 fl.

calcium salt of gopantenic acid 500 mg 10 g

Auxiliary substances: glycerol 25.8 g, sorbitol 15 g, citric acid monohydrate 0.1 g, sodium benzoate 0.1 g, aspartame 0.05 g, flavoring food Cherry 667 0.01 g, purified water 100 ml.

100 ml - bottles of dark glass (1) complete with a measuring spoon with a volume of 5 ml - packs of cardboard.

INSTRUCTION FOR THE SPECIALIST.

Description of the drug approved by the manufacturer for the printed edition of 2013.

PHARMACHOLOGIC EFFECT

The spectrum of action of Pantogam ® is related to the presence of gamma-aminobutyric acid (GABA) in its structure.
The mechanism of action is due to the direct influence of Pantogam on GABA B- receptor-channel complex.
The drug has nootropic and anticonvulsant action.

The drug increases the resistance of the brain to hypoxia and the effects of toxic substances, stimulates anabolic processes in neurons, combines moderate sedation with a mild stimulating effect, reduces motor excitability, activates mental and physical performance.
Improves the metabolism of GABA in chronic alcohol intoxication and after the abolition of ethanol. It is able to inhibit the acetylation reactions involved in the mechanisms of inactivation of procaine (novocaine) and sulfonamides, thereby prolonging the action of the latter.
It causes inhibition of the pathologically increased vesicle reflex and detrusor tone.

PHARMACOKINETICS

Suction

Quickly absorbed from the digestive tract.

Distribution

The greatest concentrations are created in the liver, kidneys, in the wall of the stomach, in the skin.
Penetrates through the BBB.
Metabolism and excretion

It is not metabolized and is excreted unchanged for 48 hours. 67.5% of the accepted dose is excreted by the kidneys, 28.5% - with feces.

INDICATIONS

- cognitive impairment with organic brain lesions (including the consequences of neuroinfections and craniocerebral trauma) and neurotic disorders;

- schizophrenia with organic cerebral insufficiency;

- cerebrovascular insufficiency, caused by atherosclerotic changes in cerebral vessels;

- extrapyramidal disorders (including myoclonus-epilepsy, Huntington's chorea, hepatolenticular degeneration, Parkinson's disease), as well as for the treatment and prevention of extrapyramidal syndrome (hyperkinetic and akinetic) caused by the administration of neuroleptics;

- epilepsy with the slowing down of mental processes in complex therapy with anticonvulsants;

- psycho-emotional overload, reduced mental and physical performance (to improve concentration and memorization);

- neurogenic disorders of urination (pollakiuria, imperative urges, mandatory urinary incontinence, enuresis);

- children with perinatal encephalopathy from the first days of life;

- various forms of infantile cerebral palsy;

- Mental retardation of various degrees, incl.
with behavioral disorders;
- Violations of the psychological status of children in the form of a general delay in mental development, specific speech disorders, motor functions and their combination, the formation of school skills (reading, writing, counting, etc.);

- hyperkinetic disorders, incl.
hyperactivity disorder with attention deficit;
- Neurosis-like conditions (with stuttering, mainly clonic form, tics, inorganic encopresis and enuresis).

DOSING MODE

Tablets and syrup are taken orally 15-30 minutes after eating.
Tablets are used in children older than 3 years, at an earlier age recommend taking the drug as a syrup.
For adults, the single dose is 0.25-1 g, the daily dose is 1.5-3 g.

For children, a single dose is 0.25-0.5 g, daily - 0.75-3 g.

Course of treatment 1-4 months, sometimes up to 6 months.
After 3-6 months, a second course of treatment can be performed.
In schizophrenia (in combination with psychotropic drugs), the drug is prescribed in a dose of 0.5-3 g / day.
The course of treatment is from 1 to 3 months.
With epilepsy (in combination with anticonvulsants), the drug is prescribed in a dose of 0.75 g to 1 g per day.
The course of treatment is up to 1 year or more.
With extrapyramidal neuroleptic syndrome (in combination with the therapy), the dose is up to 3 g / day.
Treatment is carried out for several months.
With extrapyramidal hyperkinesias, patients with hereditary diseases of the nervous system (in combination with the therapy administered ) are prescribed from 0.5 g to 3 g per day.
The course of treatment - up to 4 months or more.
At the consequences of neuroinfections and craniocerebral injuries - 0.25 g 3-4 times / day.

To restore efficiency with increased loads and asthenic conditions Pantogam prescribed 0.25-0.5 g 3 times / day.

For the treatment of extrapyramidal syndrome caused by the administration of neuroleptics , adults - 0.5-1 g 3 times / day, children - 0.25-0.5 g 3-4 times / day.
The course of treatment is 1-3 months.
At ticks to children - to 0.25-0.5 g 3-6 times / day for 1-4 months.

For violations of urination, adults are prescribed a dose of 0.5-1 g 2-3 times / day, children - 0.25-0.5 g (daily dose is 25-50 mg / kg).
The course of treatment is 1-3 months.
Children with different pathologies of the nervous system, depending on age, are recommended the following range of doses: children of the first year of life - 0.5-1 g / day, children under the age of 3 years - 0.5-1.25 g / day, children from 3 to 7 years - 0.75- 1.5 g / day, children over 7 years - 1-2 g / day.
The tactics of prescribing the drug consists in gradually increasing the dose for 7-12 days, taking in the maximum dose for 15-40 days and gradually reducing the dose for 7-8 days until the complete removal of Pantogam. The course of treatment is 30-90 days (for certain diseases up to 6 months and more).
The break between the Pantogam course is 1-3 months (as for any other nootropic remedy).

Given the nootropic effect of the drug, it is taken in the morning and afternoon hours (up to 17 hours).

SIDE EFFECT

Allergic reactions: there may be rhinitis, conjunctivitis, skin rashes (it may be necessary to cancel the drug or reduce the dose).

Other: there may be sleep disturbance or drowsiness, noise in the head (these symptoms are usually short-lived and do not require drug withdrawal).

CONTRAINDICATIONS

- Acute severe kidney disease;

- Pregnancy;

- lactation;

- phenylketonuria (for syrup, as it contains aspartame);

- Hypersensitivity to the drug.

PREGNANCY AND LACTATION

The drug is not recommended for use in pregnancy and lactation (breastfeeding) due to the lack of data on efficacy and safety.

APPLICATION FOR FUNCTIONS OF THE LIVER

The drug is contraindicated in acute severe kidney disease.

APPLICATION FOR CHILDREN

Children are prescribed according to the indications in the recommended doses.

SPECIAL INSTRUCTIONS

With prolonged treatment, simultaneous administration of Pantogam with other nootropic drugs and CNS stimulating agents is not recommended.

Impact on the ability to drive vehicles and manage mechanisms

In the first days of taking the drug should be careful when driving vehicles and mechanisms, given the possible occurrence of drowsiness.

OVERDOSE

Symptoms: increased symptoms of the described side effects (sleep disturbance or drowsiness, noise in the head).

Treatment: activated charcoal, gastric lavage;
if necessary, conduct symptomatic therapy.
DRUG INTERACTION

Pantogam ® prolongs the action of barbiturates, enhances the effects of anticonvulsants.

When combined, Pantogam ® prevents side effects of phenobarbital, carbamazepine, neuroleptics.

The effect of Pantogam is enhanced by simultaneous use with glycine, etidronic acid.

Pantogam ® potentiates the action of local anesthetics (procaine).

TERMS OF RELEASE FROM PHARMACY

The drug is released by prescription.

TERMS AND CONDITIONS OF STORAGE

The drug should be stored in a dry, protected from light and out of reach of children at a temperature of no higher than 25 ° C.
Shelf life of tablets 250 mg - 4 years, tablets 500 mg - 3 years, syrup - 2 years.
After opening, store the vial with the syrup in the refrigerator for no more than 1 month.

Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y
Rambler's Top100
Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!